TranS1 Price Target Cut to $4.00 (TSON)
TranS1 (NASDAQ: TSON) had its price target lowered by Piper Jaffray from $5.00 to $4.00 in a research report released on Tuesday morning. Piper Jaffray currently has an overweight rating on the stock.
“The Baxano acquisition announcement was a surprise, in part because TranS1 has been more often viewed as a potential target than an acquirer. However, the synergies of multiple lines of differentiated MIS technologies, serving specialists within spine surgery focusing on MIS makes strategic sense to us, and the deal also scales up the growth model significantly for the company over the next 2-3 years. … We reiterate our Overweight rating on TSON, trimming our target slightly from $5 to $4 due primarily to dilution.,” Piper Jaffray’s analyst commented.
Shares of TranS1 opened at 2.32 on Tuesday. TranS1 has a one year low of $2.05 and a one year high of $3.87. The stock’s 50-day moving average is currently $2.45. The company’s market cap is $63.3 million.
A number of other firms have also recently commented on TSON. Analysts at JMP Securities initiated coverage on shares of TranS1 in a research note to investors on Wednesday, February 13th. They set an outperform rating and a $4.00 price target on the stock. Separately, analysts at Brean Murray initiated coverage on shares of TranS1 in a research note to investors on Friday, February 1st. They set a buy rating and a $4.75 price target on the stock. Finally, analysts at Barrington Research initiated coverage on shares of TranS1 in a research note to investors on Monday, December 31st. They set an outperform rating on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.